Premium
Swallowing and speech ability after treatment for head and neck cancer with targeted intraarterial versus intravenous chemoradiation
Author(s) -
Newman Lisa A.,
Thomas Robbins K.,
Logemann Jeri A.,
Rademaker Alfred W.,
Lazarus Cathy L.,
Hamner Annette,
Tusant Stephanie,
Huang Cheng Fang
Publication year - 2002
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.10000
Subject(s) - swallowing , head and neck cancer , medicine , cisplatin , radiation therapy , head and neck , cancer , anesthesia , surgery , chemotherapy
Objective RADPLAT (concurrent selective supradose intraarterial cisplatin and external‐beam irradiation) delivers extraordinarily high cisplatin concentration to head and neck structures. This study was designed to quantify and compare RADPLAT and systemic chemoradiation treatment effects on swallowing and speech. Methods Videofluorographic swallowing studies and articulation testing of 14 head and neck cancer patients treated with RADPLAT were compared with 16 treated with systemic chemoradiation 1 month after treatment. Results RADPLAT and systemic chemoradiation patients did not differ significantly on most swallow outcome measures, and there was significantly less aspiration on 1 and 3 mL liquid for RADPLAT individuals. Speech function was comparable except for RADPLAT's significantly worse /s, z/ productions. Conclusions Increased concentration of cisplatin to the head and neck did not result in generally reduced swallowing or articulatory function. © 2002 John Wiley & Sons, Inc. Head Neck 24: 68–77, 2002.